DSM-Firmenich AG (NL:DSFIR)
:DSFIR
Want to see NL:DSFIR full AI Analyst Report?
Top Page
DSM-Firmenich AG
(DSFIR)
Select Model
Select Model
Rating:52Neutral
Price Target:
€67.00
▲(1.89% Upside)
Action:Reiterated
Date:02/18/26
The score is held back primarily by unstable financial performance (notably the 2025 revenue drop and net loss) and bearish technicals (below key moving averages with weak momentum). A relatively sound balance sheet and positive cash flow, along with an above-average dividend yield, provide partial support but do not offset the elevated near-term performance risk.
Positive Factors
Diversified B2B ingredient portfolio and embedded services
Broad product mix across perfumery, flavors, functional food and nutrition plus application labs and co‑creation creates durable, sticky B2B relationships. Multi-segment exposure and value‑added services increase customer switching costs and support recurring revenue over months to years.
Negative Factors
Volatile revenue with sharp 2025 decline
Large swings in top-line create forecasting difficulty and reduce the visibility needed for long-term planning. Volatile revenue undermines stable capacity utilization and can depress bargaining leverage with suppliers and customers, raising execution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Diversified B2B ingredient portfolio and embedded services
Broad product mix across perfumery, flavors, functional food and nutrition plus application labs and co‑creation creates durable, sticky B2B relationships. Multi-segment exposure and value‑added services increase customer switching costs and support recurring revenue over months to years.
Read all positive factors
DSM-Firmenich AG (DSFIR) vs. iShares MSCI Netherlands ETF (EWN)
Market Cap
€15.81B
Dividend Yield3.61%
Average Volume (3M)727.24K
Price to Earnings (P/E)―
Beta (1Y)0.65
Revenue Growth-29.42%
EPS Growth-564.23%
CountryNL
Employees26,301
SectorBasic Materials
Sector Strength58
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-4.16
Shares Outstanding253,626,950
10 Day Avg. Volume620,056
30 Day Avg. Volume727,238
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.98
Price to Sales (P/S)1.97
P/FCF Ratio28.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€74.57Price Target Upside13.40% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)3.49
Revenue Forecast (FY)€9.17B
DSM-Firmenich AG Business Overview & Revenue Model
Company Description
DSM-Firmenich AG, a science-based company, engages in beauty, health, and nutrition businesses in the Netherlands, Switzerland, rest of Europe, North America, Latin America, China, rest of Asia, and internationally. It operates through Perfumery &...
How the Company Makes Money
DSM-Firmenich primarily makes money by selling ingredient solutions and formulations to business customers (B2B), with revenue largely driven by (1) Perfumery & Beauty: supplying fragrances, accords, and specialty ingredients used in fine fragranc...
DSM-Firmenich AG Financial Statement Overview
Summary
Income Statement
46
Neutral
Balance Sheet
72
Positive
Cash Flow
58
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 9.03B | 12.80B | 10.63B | 8.39B | 11.44B |
| Gross Profit | 3.53B | 4.25B | 2.61B | 2.78B | 4.19B |
| EBITDA | 3.85B | 561.00M | 822.00M | 1.31B | 1.45B |
| Net Income | -1.08B | 250.00M | 2.14B | 460.00M | 872.00M |
Balance Sheet | |||||
| Total Assets | 29.34B | 33.75B | 34.27B | 17.40B | 16.02B |
| Cash, Cash Equivalents and Short-Term Investments | 1.90B | 2.72B | 2.56B | 2.88B | 2.05B |
| Total Debt | 5.66B | 5.37B | 4.83B | 3.06B | 3.10B |
| Total Liabilities | 10.92B | 11.05B | 11.20B | 6.56B | 6.62B |
| Stockholders Equity | 18.24B | 22.51B | 22.91B | 10.74B | 9.32B |
Cash Flow | |||||
| Free Cash Flow | 624.00M | 1.01B | 710.00M | 279.00M | 994.00M |
| Operating Cash Flow | 1.39B | 1.78B | 1.26B | 923.00M | 1.43B |
| Investing Cash Flow | 392.00M | -252.00M | -726.00M | 871.00M | 208.00M |
| Financing Cash Flow | -2.58B | -1.33B | -820.00M | -598.00M | -984.00M |
DSM-Firmenich AG Technical Analysis
Positive
65.76
Price Trends
61.24
Positive
64.62
Positive
71.79
Negative
Market Momentum
1.07
Negative
69.92
Neutral
92.30
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NL:DSFIR, the sentiment is Positive. The current price of 65.76 is above the 20-day moving average (MA) of 61.41, above the 50-day MA of 61.24, and below the 200-day MA of 71.79, indicating a neutral trend. The MACD of 1.07 indicates Negative momentum. The RSI at 69.92 is Neutral, neither overbought nor oversold. The STOCH value of 92.30 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NL:DSFIR.
DSM-Firmenich AG Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | €8.38B | 22.64 | 14.61% | 3.38% | -7.05% | 32.41% | |
61 Neutral | $10.43B | 7.12 | -0.05% | 2.87% | 2.86% | -36.73% | |
58 Neutral | €38.86B | 16.76 | 6.11% | 1.24% | -5.78% | 142.48% | |
55 Neutral | €3.38B | 204.73 | -0.24% | 5.41% | -4.14% | -87.08% | |
53 Neutral | €1.25B | 26.37 | 6.84% | 1.46% | 11.26% | 11.66% | |
53 Neutral | €796.81M | ― | ― | 229.25% | ― | ― | |
52 Neutral | €15.81B | -2.82 | ― | 3.61% | -29.42% | -564.23% |
* Basic Materials Sector Average
NL:DSFIR
DSM-Firmenich AG
66.00
-27.97
-29.76%
NL:AKZA
Akzo Nobel NV
49.00
-8.48
-14.76%
NL:AMG
AMG ADVANCED METALLURGICAL GROUP NV
38.88
19.69
102.65%
NL:APAM
Aperam S.A.
47.50
21.90
85.55%
NL:MT
ArcelorMittal
52.24
25.01
91.84%
NL:OCI
OCI N.V.
3.78
-0.96
-20.30%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.